Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

9.96

Margin Of Safety %

-33

Put/Call OI Ratio

0.06

EPS Next Q Diff

0.19

EPS Last/This Y

-6.34

EPS This/Next Y

2.93

Price

95.25

Target Price

92.69

Analyst Recom

1.23

Performance Q

63.33

Relative Volume

1.09

Beta

2.25

Ticker: PTGX




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-13PTGX83.310.320.2920806
2025-11-14PTGX84.690.320.0720953
2025-11-17PTGX84.760.320.2120993
2025-11-18PTGX84.030.320.1021359
2025-11-19PTGX84.730.320.0321393
2025-11-20PTGX84.170.320.2121360
2025-11-21PTGX85.40.320.0021447
2025-11-24PTGX87.750.050.2613391
2025-11-25PTGX89.870.050.1013564
2025-11-26PTGX90.070.050.0013661
2025-12-01PTGX85.570.050.4913841
2025-12-02PTGX84.660.060.1713902
2025-12-03PTGX86.040.060.5613937
2025-12-04PTGX87.350.060.3113941
2025-12-05PTGX89.620.060.1714165
2025-12-08PTGX89.770.060.0014211
2025-12-09PTGX88.580.060.0114276
2025-12-10PTGX91.90.060.2714572
2025-12-11PTGX92.180.060.0014888
2025-12-12PTGX95.370.060.0215041
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-13PTGX83.19-129.0- -1.88
2025-11-14PTGX84.61-128.3- -1.87
2025-11-17PTGX84.76-128.3- -1.87
2025-11-18PTGX84.44-128.3- -1.87
2025-11-19PTGX85.13-128.3- -1.87
2025-11-20PTGX84.16-128.3- -1.87
2025-11-21PTGX85.47-128.3- -1.87
2025-11-24PTGX87.72-128.3- -1.87
2025-11-25PTGX89.86-128.3- -1.87
2025-11-26PTGX90.08-128.3- -1.87
2025-12-01PTGX85.64-128.3- -1.87
2025-12-02PTGX84.65-128.3- -1.87
2025-12-03PTGX86.07-128.3- -1.87
2025-12-04PTGX87.33-128.3- -1.87
2025-12-05PTGX89.65-128.3- -1.87
2025-12-08PTGX90.25-128.3- -1.87
2025-12-09PTGX88.56-128.3- -1.87
2025-12-10PTGX91.37-128.3- -1.87
2025-12-11PTGX92.20-128.3- -1.87
2025-12-12PTGX95.25-128.3- -1.87
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-13PTGX-2.906.599.25
2025-11-14PTGX-2.906.599.25
2025-11-17PTGX-2.908.649.25
2025-11-18PTGX-2.908.649.25
2025-11-19PTGX-2.978.649.25
2025-11-20PTGX-2.978.649.25
2025-11-21PTGX-2.978.649.25
2025-11-24PTGX-2.97-0.349.25
2025-11-25PTGX-2.98-0.349.25
2025-11-26PTGX-2.98-0.349.45
2025-12-01PTGX-2.98-0.199.45
2025-12-02PTGX-2.98-0.199.45
2025-12-03PTGX-2.98-0.199.45
2025-12-04PTGX-2.98-0.199.45
2025-12-05PTGX-2.98-0.199.45
2025-12-08PTGX-2.98-0.269.45
2025-12-09PTGX-2.98-0.269.45
2025-12-10PTGX-2.98-0.269.96
2025-12-11PTGX-2.98-0.269.96
2025-12-12PTGX-2.43-0.269.96
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

[stock_market_widget type="chart" template="candlestick" assets="PTGX" range="1y" interval="1d" price_field="close" heading="{symbol}" candle_border_width="1" candle_bullish_background_color="#21BA45" candle_bearish_background_color="#DB2828" candle_bullish_border_color="#21BA45" candle_bearish_border_color="#DB2828" axes_color="#000000" tooltip_text_color="#262626" tooltip_background_color="#ffffff" range_selector="true" volume_enabled="true" axes_enabled="true" tooltip_enabled="false" zoom_enabled="true" save_image_enabled="true" volume_bar_fill_color="#5679FF" api="yahoo-finance"]

Last Quarter Act. EPS

-0.62

Avg. EPS Est. Current Quarter

-0.56

Avg. EPS Est. Next Quarter

-0.43

Insider Transactions

-2.43

Institutional Transactions

-0.26

Beta

2.25

Average Sales Estimate Current Quarter

34

Average Sales Estimate Next Quarter

21

Fair Value

63.7

Quality Score

53

Growth Score

59

Sentiment Score

83

Actual DrawDown %

-2.1

Max Drawdown 5-Year %

-85.8

Target Price

92.69

P/E

150.54

Forward P/E

111.73

PEG

P/S

28.49

P/B

9.23

P/Free Cash Flow

93.56

EPS

0.63

Average EPS Est. Cur. Y​

-1.87

EPS Next Y. (Est.)

1.06

Target Price Estimates Raised

1

Target Price Estimates Lowered

Profit Margin

21.94

Relative Volume

1.09

Return on Equity vs Sector %

-19.8

Return on Equity vs Industry %

-4.8

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

[stock_market_widget type=”table-options” template=”gradient” color=”#5679FF” assets=”PTGX” fields=”contract_symbol,type,strike,price,change_pct,implied_volatility,change_abs,open_interest,volume,in_the_money,bid,ask” pagination=”true” rows_per_page=”21″ sort_direction=”asc” alignment=”left” search=”true” sort_field=”strike” api=”yahoo-finance”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”PTGX” options_type=”calls” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”PTGX” options_type=”puts” x_axis_field=”strike” y_axis_field=”price” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”PTGX” options_type=”calls” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”PTGX” options_type=”puts” x_axis_field=”strike” y_axis_field=”implied_volatility” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”PTGX” options_type=”calls” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
[stock_market_widget type=”chart-options” template=”basic” color=”#5679FF” assets=”PTGX” options_type=”puts” x_axis_field=”strike” y_axis_field=”volume” axes=”true” cursor=”true” display_currency_symbol=”true” api=”yf”]
Protagonist Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 128
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today
news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance
stock history PTGX – Protagonist Therapeutics Inc invest stock market
stock prices PTGX premarket after hours
ticker PTGX fair value insiders trading